参考文献/References:
[1]Semsarian C,Ingles J,Maron MS,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2015,65(12):1249-1254.
[2]国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国分子心脏病学杂志,2023,23(1):5115-5149.
[3]Elliott PM,Anastasakis A,Borger MA,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
[4]Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol ,2020,76(25):e159-e240.
[5]Marian AJ,Braunwald E. Hypertrophic cardiomyopathy:genetics,pathogenesis,clinical manifestations,diagnosis,and therapy[J]. Circ Res,2017,121(7):749-770.
[6]Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet,1995,346(8969):211-214.
[7]Veselka J,Jensen MK,Liebregts M,et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy:results from the Euro-ASA registry[J]. Eur Heart J,2016,37(19):1517-1523.
[8]Agarwal S,Tuzcu EM,Desai MY,et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,55(8):823-834.
[9]Singh K,Qutub M,Carson K,et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy[J]. Catheter Cardiovasc Interv,2016,88(1):107-115.
[10]Veselka J,Faber L,Liebregts M,et al. Sex-related differences in outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J]. JACC Cardiovasc Interv,2021,14(12):1390-1392.
[11]Liebregts M,Vriesendorp PA,Mahmoodi BK,et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy[J]. JACC Heart Fail,2015,3(11):896-905.
[12]Kimmelstiel C,Zisa DC,Kuttab JS,et al. Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes[J]. Circ Cardiovasc Interv,2019,12(7):e007673.
[13]Mateo JJS,Gimeno JR. Alcohol septal ablation in hypertrophic cardiomyopathy[J]. Glob Cardiol Sci Pract,2018,2018(3):30.
[14]Liu L,Liu B,Li J,et al. Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy:a novel minimally invasive treatment for reduction of outflow tract obstruction[J]. EuroIntervention,2018,13(18):e2112-e2113.
[15]Liu L,Li J,Zuo L,et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(16):1898-1909.
[16]Liu LW,Zuo L,Zhou MY,et al. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy][J]. Zhonghua Xin Xue Guan Bing Za Zhi,2019,47(4):284-290.
[17]Qian D,Zhou X,Liu H,et al. Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy[J]. J Clin Ultrasound,2021,49(6):554-562.
[18]Zhou M,Ta S,Hahn RT,et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy[J]. JAMA Cardiol,2022,7(5):529-538.
[19]Cooper RM ,Shahzad A,Hasleton J,et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy:a novel use of CARTOSound? technology to guide ablation[J]. Europace,2016,18(1):113-120.
[20]蒋周芩,舒茂琴,柴虹,等. CARTOSound引导下射频消融治疗肥厚型梗阻性心肌病患者的临床效果[J]. 第三军医大学学报,2021,43(8):736-740.
[21]Jiang T,Huang B,Huo S,et al. Endocardial radiofrequency ablation vs. septal myectomy in patients with hypertrophic obstructive cardiomyopathy:a systematic review and meta-analysis[J]. Front Surg ,2022,9:859205.
[22]Liu Q,Qiu H,Jiang R,et al. Selective interventricular septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy:who can benefit?[J]. Front Cardiovasc Med ,2021,8:743044.
[23]Borisov KV. Surgery of hypertrophic obstructive cardiomyopathy in patients with severe hypertrophy ,myocardial fibrosis,and ventricular tachycardia[J]. Ann Thorac Surg,2018,106(1):30-37.
[24]Messmer BJ. Extended myectomy for hypertrophic obstructive cardiomyopathy[J]. Ann Thorac Surg,1994,58(2):575-577.
[25]Delmo Walter EM,Siniawski H,Hetzer R. Sustained improvement after combined anterior mitral valve leaflet retention plasty and septal myectomy in preventing systolic anterior motion in hypertrophic obstructive cardiomyopathy in children[J]. Eur J Cardiothorac Surg,2009,36(3):546-552.
[26]Hong JH,Schaff HV,Nishimura RA,et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy:implications for concomitant valve procedures[J]. J Am Coll Cardiol ,2016,68(14):1497-1504.
[27]Thomas F,Rader F,Siegel RJ. The use of mitraclip for symptomatic patients with hypertrophic obstructive cardiomyopathy[J]. Cardiology ,2017,137(1):58-61.
[28]Long A,Mahoney P. Use of MitraClip to target obstructive SAM in severe diffuse-type hypertrophic cardiomyopathy:case report and review of literature[J]. J Invasive Cardiol,2020,32(9):E228-E232.
[29]唐亚捷,刘健,陈钊,等. 胸腔镜下经二尖瓣入路心肌切除术治疗肥厚型梗阻性心肌病的早期效果[J]. 中华胸心血管外科杂志,2020,36(8):472-477.
[30]C J AK,Marc Gillinov A,Smedira NG,et al. Robotic trans-mitral septal myectomy and papillary muscle reorientation for HOCM combined with or without mitral valve repair :technical aspects—How we do it[J]. J Card Surg,2020,35(11):3120-3124.
[31]Fang J,Liu Y,Zhu Y,et al. First-in-human transapical beating-heart?septal myectomy in patients with hypertrophic obstructive?cardiomyopathy[J]. J Am Coll Cardiol,2023,82(7):575-586.
[32]Fananapazir L,Epstein ND,Curiel RV,et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy[J]. Circulation,1994,90(6):2731-2742.
[33]Ito T,Suwa M,Sakai Y,et al. Usefulness of tissue Doppler imaging for demonstrating altered septal contraction sequence during dual-chamber pacing in obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol,2005,96(11):1558-1562.
[34]Gilligan DM. Dual-chamber pacing in hypertrophic cardiomyopathy[J]. Curr Cardiol Rep,2000,2(2):154-159.
[35]Jurado Román A,Montero Cabezas JM,Rubio Alonso B,et al. Sequential atrioventricular pacing in patients with hypertrophic cardiomyopathy:an 18-year experience[J]. Rev Esp Cardiol (Engl Ed) ,2016,69(4):377-383.
[36]Maron BJ,Shen WK,Link MS,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy[J]. N Engl J Med,2000,342(6):365-373.
[37]Maron MS,Rowin EJ,Wessler BS,et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy[J]. JAMA Cardiol,2019,4(7):644-657.
[38]O’mahony C,Jichi F,Pavlou M,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)[J]. Eur Heart J,2014,35(30):2010-2020.
相似文献/References:
[1]熊峰.梗阻性肥厚型心肌病治疗方法的现状与进展[J].心血管病学进展,2019,(6):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
XIONG Feng.Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(2):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
[2]左鹏程 莫绪明.婴幼儿主动脉缩窄术后再狭窄的诊疗进展[J].心血管病学进展,2021,(3):216.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.006]
ZUO Pengcheng,MO Xuming.Diagnosis and Treatment of Restenosis after Aortic Coarctation in Infants[J].Advances in Cardiovascular Diseases,2021,(2):216.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.006]
[3]文琰 杨谋 胡宏德.梗阻性肥厚型心肌病缓解梗阻的治疗进展[J].心血管病学进展,2022,(9):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
WEN Yan,YANG Mou,HU Hongde.Obstruction Relief Therapy in Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(2):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
[4]龚勇泉?农巍?吴先球?卢天成?韦成信.弓部受累的主动脉病变治疗应用进展[J].心血管病学进展,2023,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.019]
GONG Yongquan,NONG Wei,WU Xianqiu,et al.Treatment of Aortic Diseases Involving Arch[J].Advances in Cardiovascular Diseases,2023,(2):658.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.019]
[5]胡雪梅 胥雪莲 唐炯.血管迷走性晕厥介入治疗的研究进展[J].心血管病学进展,2023,(8):690.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.005]
HU Xuemei,XU Xuelian,TANG Jiong.Interventional Therapy of Vasovagal Syncope[J].Advances in Cardiovascular Diseases,2023,(2):690.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.005]
[6]董震宇 穆耶赛尔·玉苏普 芦颜美 汤宝鹏.介入器械治疗慢性心力衰竭的研究进展[J].心血管病学进展,2023,(12):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]
DONG Zhenyu,Muyassar·Yusup,LU Yanmei,et al.Device-based Interventional Strategies for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(2):1061.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023. 12. 002]
[7]常羽茜 李昱熙 刘旭 刘志浩 张岩.肾动脉狭窄介入治疗中的血流动力学评估进展[J].心血管病学进展,2024,(3):196.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.002]
CHANG Yuxi,LI Yuxi,LIU Xu,et al.Hemodynamic Evaluation in Interventional Treatment of Renal Artery Stenosis[J].Advances in Cardiovascular Diseases,2024,(2):196.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.002]